News

Latest draft work programme of cluster 5: climate, energy and mobility now available

Published on | 4 years ago

Programmes Energy Transport Climate/Environment

The launch of the full Horizon Europe programme is now very close.

Here you can find the latest version of the work programme for cluster 5 climate, energy and mobility.

This is still a draft version so minor changes to the texts are still possible.

If you want information regarding the background of these calls you can contact the PC representatives lut.bollen@vlaanderen.be (energy/climate) and hilde.vermeulen@vlaanderen.be (mobility)

You can also email the NCP’s bart.decaesemaeker@vlaio.be and pascal.verheye@vlaio.be  if you would like to receive more information on the NCP services regarding Horizon Europe.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1725 articles available search in articles 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.